Insilico Medicine, a biotech startup, has developed the first fully AI-generated drug, INS018_055, which has entered clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF). IPF is a chronic lung disease that can be fatal if left untreated. The drug was created using artificial intelligence to discover a novel target and design a new molecule. Insilico Medicine has chosen to focus on IPF due to its implications in aging. The company also has two other AI-generated drugs in the clinical stage, one for Covid-19 and another for solid tumors. The current clinical trial for the IPF drug is taking place in China and will later expand to the US. If successful, the drug will proceed to larger studies. Results from the current phase two trial are expected next year, and the drug could potentially be on the market in the next few years.
